
Ebenezer O Sackey
Examiner (ID: 17838, Phone: (571)272-0704 , Office: P/1624 )
| Most Active Art Unit | 1624 |
| Art Unit(s) | 1613, 1201, 1626, 1624, 1621 |
| Total Applications | 2086 |
| Issued Applications | 1598 |
| Pending Applications | 91 |
| Abandoned Applications | 399 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17236602
[patent_doc_number] => 11180473
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-11-23
[patent_title] => PLXDC2 ligands
[patent_app_type] => utility
[patent_app_number] => 17/212425
[patent_app_country] => US
[patent_app_date] => 2021-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 44
[patent_no_of_words] => 20586
[patent_no_of_claims] => 55
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 300
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17212425
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/212425 | PLXDC2 ligands | Mar 24, 2021 | Issued |
Array
(
[id] => 16991753
[patent_doc_number] => 20210230173
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-29
[patent_title] => HETEROCYCLIC LSF INHIBITORS AND THEIR USES
[patent_app_type] => utility
[patent_app_number] => 17/155547
[patent_app_country] => US
[patent_app_date] => 2021-01-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34671
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 340
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17155547
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/155547 | Heterocyclic LSF inhibitors and their uses | Jan 21, 2021 | Issued |
Array
(
[id] => 17134761
[patent_doc_number] => 11136307
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2021-10-05
[patent_title] => Crystalline form of tegavivint, method of preparation, and use thereof
[patent_app_type] => utility
[patent_app_number] => 17/037287
[patent_app_country] => US
[patent_app_date] => 2020-09-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 40
[patent_no_of_words] => 5307
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17037287
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/037287 | Crystalline form of tegavivint, method of preparation, and use thereof | Sep 28, 2020 | Issued |
Array
(
[id] => 16523678
[patent_doc_number] => 20200397758
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-24
[patent_title] => Antimitotic Amides for the Treatment of Cancer and Proliferative Disorders
[patent_app_type] => utility
[patent_app_number] => 17/011589
[patent_app_country] => US
[patent_app_date] => 2020-09-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27530
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 212
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17011589
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/011589 | Antimitotic amides for the treatment of cancer and proliferative disorders | Sep 2, 2020 | Issued |
Array
(
[id] => 16452520
[patent_doc_number] => 20200361946
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-19
[patent_title] => Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5)
[patent_app_type] => utility
[patent_app_number] => 16/985643
[patent_app_country] => US
[patent_app_date] => 2020-08-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 46679
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -36
[patent_words_short_claim] => 120
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16985643
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/985643 | Selective inhibitors of protein arginine methytransterase 5 (PRMT5) | Aug 4, 2020 | Issued |
Array
(
[id] => 17421241
[patent_doc_number] => 11254683
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-02-22
[patent_title] => Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
[patent_app_type] => utility
[patent_app_number] => 16/985611
[patent_app_country] => US
[patent_app_date] => 2020-08-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51286
[patent_no_of_claims] => 35
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 186
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16985611
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/985611 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | Aug 4, 2020 | Issued |
Array
(
[id] => 17330041
[patent_doc_number] => 11220494
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-01-11
[patent_title] => Cyclin dependent kinase inhibitors
[patent_app_type] => utility
[patent_app_number] => 16/942209
[patent_app_country] => US
[patent_app_date] => 2020-07-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 84921
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 8
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16942209
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/942209 | Cyclin dependent kinase inhibitors | Jul 28, 2020 | Issued |
Array
(
[id] => 17323580
[patent_doc_number] => 11214574
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-01-04
[patent_title] => Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
[patent_app_type] => utility
[patent_app_number] => 16/888883
[patent_app_country] => US
[patent_app_date] => 2020-06-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51362
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16888883
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/888883 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | May 31, 2020 | Issued |
Array
(
[id] => 16297683
[patent_doc_number] => 20200283406
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-10
[patent_title] => ANTIPROLIFERATIVE PYRIMIDINE-BASED COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 16/877249
[patent_app_country] => US
[patent_app_date] => 2020-05-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33479
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 453
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16877249
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/877249 | ANTIPROLIFERATIVE PYRIMIDINE-BASED COMPOUNDS | May 17, 2020 | Abandoned |
Array
(
[id] => 16604784
[patent_doc_number] => 10905768
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2021-02-02
[patent_title] => Heterocyclic degronimers for target protein degradation
[patent_app_type] => utility
[patent_app_number] => 16/872225
[patent_app_country] => US
[patent_app_date] => 2020-05-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 389
[patent_figures_cnt] => 559
[patent_no_of_words] => 70742
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 432
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16872225
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/872225 | Heterocyclic degronimers for target protein degradation | May 10, 2020 | Issued |
Array
(
[id] => 17407114
[patent_doc_number] => 11247983
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-02-15
[patent_title] => Compounds and methods for inhibiting JAK
[patent_app_type] => utility
[patent_app_number] => 16/860169
[patent_app_country] => US
[patent_app_date] => 2020-04-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 36
[patent_figures_cnt] => 36
[patent_no_of_words] => 36039
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 99
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16860169
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/860169 | Compounds and methods for inhibiting JAK | Apr 27, 2020 | Issued |
Array
(
[id] => 16206479
[patent_doc_number] => 20200239469
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-30
[patent_title] => FORMS OF METHYL {4,6-DIAMINO-2-[1 (2-FLUOROBENZYL)-1H-PYRAZOLO[3-4-B]PYRIDINO-3-YL]PYRIMIDINO-5-YL}METHYL CARBAMATE
[patent_app_type] => utility
[patent_app_number] => 16/848249
[patent_app_country] => US
[patent_app_date] => 2020-04-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9130
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16848249
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/848249 | Forms of methyl {4,6-diamino-2-[1(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate | Apr 13, 2020 | Issued |
Array
(
[id] => 17363517
[patent_doc_number] => 11230532
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-01-25
[patent_title] => Pyrimidines and variants thereof, and uses therefor
[patent_app_type] => utility
[patent_app_number] => 16/846452
[patent_app_country] => US
[patent_app_date] => 2020-04-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45976
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 218
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16846452
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/846452 | Pyrimidines and variants thereof, and uses therefor | Apr 12, 2020 | Issued |
Array
(
[id] => 16206496
[patent_doc_number] => 20200239486
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-30
[patent_title] => PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER
[patent_app_type] => utility
[patent_app_number] => 16/847426
[patent_app_country] => US
[patent_app_date] => 2020-04-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30535
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 696
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16847426
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/847426 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | Apr 12, 2020 | Abandoned |
Array
(
[id] => 16190728
[patent_doc_number] => 20200231577
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-23
[patent_title] => ARYL SUBSTITUTED PYRIMIDINES FOR USE INFLUENZA VIRUS INFECTION
[patent_app_type] => utility
[patent_app_number] => 16/840279
[patent_app_country] => US
[patent_app_date] => 2020-04-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10705
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 76
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16840279
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/840279 | Aryl substituted pyrimidines for use in influenza virus infection | Apr 2, 2020 | Issued |
Array
(
[id] => 16876828
[patent_doc_number] => 11026948
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-06-08
[patent_title] => Platinum-resistant cancer treatment
[patent_app_type] => utility
[patent_app_number] => 16/810160
[patent_app_country] => US
[patent_app_date] => 2020-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 5
[patent_no_of_words] => 9216
[patent_no_of_claims] => 34
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 79
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16810160
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/810160 | Platinum-resistant cancer treatment | Mar 4, 2020 | Issued |
Array
(
[id] => 17015182
[patent_doc_number] => 11084808
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-08-10
[patent_title] => Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof
[patent_app_type] => utility
[patent_app_number] => 16/804180
[patent_app_country] => US
[patent_app_date] => 2020-02-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44360
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16804180
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/804180 | Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof | Feb 27, 2020 | Issued |
Array
(
[id] => 17556032
[patent_doc_number] => 11312708
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-04-26
[patent_title] => Process and intermediates for the preparation of benzo[b]thiophene compounds
[patent_app_type] => utility
[patent_app_number] => 16/785002
[patent_app_country] => US
[patent_app_date] => 2020-02-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9423
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 944
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16785002
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/785002 | Process and intermediates for the preparation of benzo[b]thiophene compounds | Feb 6, 2020 | Issued |
Array
(
[id] => 16735607
[patent_doc_number] => 10961242
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-03-30
[patent_title] => Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same
[patent_app_type] => utility
[patent_app_number] => 16/783893
[patent_app_country] => US
[patent_app_date] => 2020-02-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 52451
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 17
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16783893
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/783893 | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | Feb 5, 2020 | Issued |
Array
(
[id] => 15898347
[patent_doc_number] => 20200148692
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-14
[patent_title] => Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5)
[patent_app_type] => utility
[patent_app_number] => 16/744771
[patent_app_country] => US
[patent_app_date] => 2020-01-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 46372
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 96
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16744771
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/744771 | Selective inhibitors of protein arginine methlytransferase 5 (PRMT5) | Jan 15, 2020 | Issued |